Skip to content

Visionary Ventures

Life sciences venture capital fund investing in ophthalmology and medical aesthetics.

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Fund Menu

Search:

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Tarsus Pharmaceuticals Completes $60MM Series B Financing

Tarsus+Logo-02

Tarsus Pharmaceuticals completes $60MM Series B financing.

Click here to view the press release

Search:

Recent Posts

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™
October 9, 2024
Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma
September 13, 2024
ONL Therapeutics Closes $65 Million In Oversubscribed Series D Financing
September 13, 2024

Categories

Acquisition(2)
Aurion(4)
IanTECH(2)
Iantrek(2)
IPO(2)
License Deal(1)
News(68)
ONL(3)
Orasis(17)
Pelage(2)
Re-Vana(4)
RxSight(2)
Surface(1)
Sydnexis(3)
Tarsus(7)
Tear Film(4)
TearClear(8)
Visionary(9)

Archives

Visionary Ventures

Visionary Ventures is a venture capital fund that invests in life sciences and the future of ophthalmology and medical aesthetics. We are an opportunistic venture fund that invests in early and late stages of a company's growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $5M to $15M.

Contact Us

Visionary Ventures
620 Newport Center Drive, Suite 650
Newport Beach CA 92660
info@visionaryvc.com

Home
Ophthalmology
Team
Portfolio
News
Contact
Investor Portal

Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.